Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Research & Development for 13 consecutive years, with $40321.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 53.98% year-over-year to $40321.0, compared with a TTM value of $91407.0 through Sep 2025, down 78.79%, and an annual FY2024 reading of $283942.0, up 18.27% over the prior year.
  • Research & Development was $40321.0 for Q3 2025 at China Pharma Holdings, up from $20952.0 in the prior quarter.
  • Across five years, Research & Development topped out at $190086.0 in Q1 2021 and bottomed at $547.0 in Q4 2024.
  • Average Research & Development over 5 years is $58931.8, with a median of $40321.0 recorded in 2025.
  • Peak annual rise in Research & Development hit 592.02% in 2024, while the deepest fall reached 99.63% in 2024.
  • Year by year, Research & Development stood at $54048.0 in 2021, then plummeted by 48.2% to $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then plummeted by 99.63% to $547.0 in 2024, then surged by 7271.3% to $40321.0 in 2025.
  • Business Quant data shows Research & Development for CPHI at $40321.0 in Q3 2025, $20952.0 in Q2 2025, and $29587.0 in Q1 2025.